A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
- Registration Number
- NCT00423891
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this clinical study is to determine the appropriate doses of entecavir to use in children and adolescents. Safety, tolerability and efficacy will also be studied
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64
- 2-18 years of age
- Group A: Lamivudine naive (<1 week of Lamivudine) and not within 24 weeks of screening; Group B: Lamivudine experienced (> 12 weeks of Lamivudine); Group C: nucleoside/nucleotide experienced (> 12 weeks of nucleoside/tide therapy) added as a country-specific protocol amendment (not all sites had Group C).
- HBV Deoxyribonucleic acid (DNA) ≥ 100000 copies/mL; ≥ 10000 copies for nucleoside/nucleotide experienced (Group C)
- Detectable Hepatitis B surface antigen (HBsAg) for 24 weeks prior to screening
- Hepatitis B e antigen (HBeAg) positive
- Compensated liver and renal function
- Elevated alanine aminotransferase (ALT) at screening and during the 24 weeks prior to screening (for Groups A and B)
- Coinfection with Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Hepatitis D Virus (HDV)
- Children who were breastfed while their mother received Lamivudine, or children whose mothers received Lamivudine during pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Arm 1: Entecavir Entecavir -
- Primary Outcome Measures
Name Time Method Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment Day 1 to Week 120 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Medical Dictionary for Regulatory Activities (MedDRA) version 16.0 was used.
- Secondary Outcome Measures
Name Time Method Mean Maximum Observed Plasma Concentration (Cmax) and Mean Trough Observed Plasma Concentration (Cmin) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort Day 14 Cmax and Cmin were derived from plasma concentration of ETV versus time and measured in nanograms per milliliters (ng/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Note: PK parameters were summarized for only Groups A and B. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
Median Time of Maximum Observed Plasma Concentration (Tmax) in LVD-naive and LVD-experienced Participants, by Age Cohort Day 14 Tmax was derived from plasma concentration of ETV versus time and measured in hours (h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Age categories presented below: participants age as of first day of dosing. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
Mean Area Under the Concentration-Time Curve in One Dosing Interval [AUC(TAU)] of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort Day 14 Area under the Curve (AUC) was derived from plasma concentration of ETV versus time. AUC(TAU) was calculated by log- and linear trapezoidal summations, TAU = 24 hours, and was measured in nanograms\*hours per milliliter (ng\*h/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
Mean Apparent Total Body Clearance (CLT/F) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort At 2 weeks CLT/F was calculated by dividing the dose of ETV by AUC(TAU) of ETV and was measured in liters per hour (L/h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
Number of Participants With HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants Baseline to Week 96 Hepatitis B virus DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS TaqMan - high pure system (HPS) assay and was reported in international units per milliliter (IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants With Hepatitis B e Antigen (HBeAg) Loss Through Week 96 in Treated Participants Baseline to Week 96 HBeAg loss: HBeAg negative. The method used for the detection of HBe Ag was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants With Hepatitis B s Antigen (HBsAg) Loss Through Week 96 in Treated Participants Baseline to Week 96 HBsAg loss: HBsAg negative. The method used for detection of HBsAg was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants With Hepatitis B e Antigen Seroconversion Through Week 96 in Treated Participants Baseline through Week 96 HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HB e antibodies (HBeAb), ie both the presence of HBeAb and the absence of HBeAg. The method used for the detection HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants With HBV DNA Less Than Lower Limit of Detection (LLD) for the Roche COBAS TaqMan - HPS Assay at Week 96 in Treated Participants Baseline to Week 96 Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLD = 6 IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants With HBV DNA Less Than Lower Limit of Quantification (LLQ) for the Roche COBAS TaqMan - HPS Assay Through Week 96 in Treated Participants Baseline through Week 96 Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants With HB s Antigen (HBsAg) Seroconversion Through Week 96 in Treated Participants Baseline through Week 96 HB s Ag seroconversion: loss of HBsAg (HBsAg negative) and presence of HB s antibodies (HBsAb). The method used for the detection of HBsAg seroconversion was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants Who Had a Protocol Defined Response (PDR) Through Week 96 in Treated Participants Baseline to Week 96 PDR was defined as confirmed HBV DNA \< 50 IU/mL plus confirmed HBeAg seroconversion on 2 sequential measurements at least 14 days apart. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Mean Log10 Change From Baseline in HBV DNA Using Roche COBAS TaqMan - HPS Through Week 96 in Treated Participants Baseline to Week 96 Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. HBV DNA log10 changes from baseline were summarized over time.
Alanine Aminotransferase (ALT) Normalization From Baseline Through Week 96 in Treated Participants Baseline to Week 96 Normalization in ALT= ALT ≤ 1.0\*upper limit of normal (ULN). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants With HBV DNA by PCR Categories at Weeks 48 and 96 in Treated Participants Baseline, Week 48, Week 96 Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants Baseline to Week 96 Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN.
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Plus HBeAg Seroconversion Through Week 96 in Treated Participants Baseline to Week 96 Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion was determination of presence of HBeAb and loss of HBeAg. The method used for the detection of HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit.
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Without HBeAg Seroconversion, Through Week 96 in Treated Participants Baseline to Week 96 Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HBeAb. The method used for the detection of HBeAg/Ab serologies was the DiaSorin enzyme immunoassay kit.
Number of Participants With Hematology Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants Day 1 to Week 120 Toxicity Scale: Division of AIDs (DAIDS) grades Version 1.0. Upper limit of normal (ULN); lower limit of normal (LLN); Cells per Liter (c/L); cells per microliter (c/µL); grams per deciliter (g/dL); milliequivalents per liter (mEq/L); cells per microliter (c/µL): Grade (Gr). Hemoglobin g/dL: Gr1:10.0-10.9;Gr2: 9.0-9.9; Gr3:7.0-8.9; Gr4: \<7.0. International normalization ratio (INR): Gr1:1.1-\<1.5\*ULN; Gr2: 1.6-\<2.0\*ULN; Gr3: 2.1-3.0\*ULN;Gr4: \>3.0\*ULN. Neutrophils/bands c/µL: Gr1;1.0-1.3\*10\^3; Gr2: 0.75-0.99\*10\^3; Gr 3: 0.50-0.749\*10\^3; Gr4: \<0.5\*10\^3.
Number of Participants With Chemistry Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants Day 1 to Week 120 Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO). Grade (Gr). ALT: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0 \*ULN; Gr3: 5.1-10.0\*ULN; Gr4:\>10.0\*ULN. Aspartate aminotransferase (AST): Gr1: 1.25-\<2.5\*ULN; Gr2:2.6-\<5.0\*ULN; Gr 3: 5.1-10.0\*ULN; Gr4\>10.0\*ULN. Alkaline phosphatase: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0\*ULN; Gr3: 5.1-10.0\*ULN; Gr4: \>10.0\*ULN. Lipase: Gr1:1.1-\<1.5\*ULN;Gr2:1.6-\<3.0\*ULN; Gr3: 3.1-5.0\*ULN; Gr4: \>5.0\*ULN. Creatinine: Gr1: 1.1-1.3\*ULN; Gr2: 1.4-\<1.8\*ULN; Gr3: 1.9 - \<3.4\*ULN; Gr4: \>=3.5\*ULN. Glucose mg/dL (high): Gr1:110-\<125 (Fasting)/116-\<160;Gr2:126-\<250 (F)/161-\<250; Gr3: 251-500; Gr4: \>500.Glucose (low): Gr1: 55-64; Gr2: 40 - \<54; Gr3: 30-39; Gr4: \<30 mg/dL.
Number of Participants With Electrolyte Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants Day 1 Week 120 Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO) for chloride. Milliequivalents per liter (mEq/L); Grade (Gr). Chloride high (mEq/L): Gr1: 113-\<117; Gr2: 117-\<121; Gr3: 121-125; Gr4: \>125. Potassium low (mEq/L): Gr1: 3.0-3.4; Gr2: 2.5-2.9; Gr3:2.0-\<2.4; Gr4: \<2.0. Potassium high: Gr1; 5.6- \<6.0; Gr2: 6.1-\<6.5; Gr3: 6.6-7.0; Gr4: \>7.0. Sodium high (mEq/L): Gr1; 146-\<150; Gr2: 151-\<154; Gr3: 155-\<159; Gr4: \>=160.
Trial Locations
- Locations (10)
Connecticut Children'S Medical Center
🇺🇸Hartford, Connecticut, United States
University of California, San Francisco
🇺🇸San Francisco, California, United States
Mount Sinai School Of Medicine
🇺🇸New York, New York, United States
University Of Florida
🇺🇸Gainesville, Florida, United States
Boston Childrens Hospital
🇺🇸Boston, Massachusetts, United States
Children'S Hospital Of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
Local Institution
🇬🇧Birmingham, West Midlands, United Kingdom
University Of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Johns Hopkins School Of Medicine
🇺🇸Baltimore, Maryland, United States
Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States